South Korea
· Delayed Price · Currency is KRW Prestige BioPharma Statistics
Total Valuation
Prestige BioPharma has a market cap or net worth of KRW 170.19 billion. The enterprise value is 122.90 billion.
| Market Cap | 170.19B |
| Enterprise Value | 122.90B |
Important Dates
The last earnings date was Thursday, September 19, 2024.
| Earnings Date | Sep 19, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Prestige BioPharma has 12.02 million shares outstanding.
| Shares Outstanding | 12.02M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.45% |
| Owned by Insiders (%) | 30.40% |
| Owned by Institutions (%) | 0.10% |
| Float | 3.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 9.69 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.73 |
| EV / Sales | 178.35 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.80 |
Financial Position
The company has a current ratio of 1.72, with a Debt / Equity ratio of 0.20.
| Current Ratio | 1.72 |
| Quick Ratio | 1.57 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.54 |
| Interest Coverage | -8.41 |
Financial Efficiency
Return on equity (ROE) is -10.38% and return on invested capital (ROIC) is -6.07%.
| Return on Equity (ROE) | -10.38% |
| Return on Assets (ROA) | -5.35% |
| Return on Capital (ROIC) | -6.07% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.10 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +33.08% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +33.08% |
| 50-Day Moving Average | 13,973.40 |
| 200-Day Moving Average | 10,114.90 |
| Relative Strength Index (RSI) | 51.09 |
| Average Volume (20 Days) | 148,990 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Prestige BioPharma had revenue of KRW 689.08 million and -32.92 billion in losses. Loss per share was -547.81.
| Revenue | 689.08M |
| Gross Profit | -528.79M |
| Operating Income | -62.24B |
| Pretax Income | -54.69B |
| Net Income | -32.92B |
| EBITDA | -45.97B |
| EBIT | -62.24B |
| Loss Per Share | -547.81 |
Balance Sheet
The company has 228.81 billion in cash and 105.11 billion in debt, giving a net cash position of 123.71 billion or 10,292.51 per share.
| Cash & Cash Equivalents | 228.81B |
| Total Debt | 105.11B |
| Net Cash | 123.71B |
| Net Cash Per Share | 10,292.51 |
| Equity (Book Value) | 515.50B |
| Book Value Per Share | 1,461.28 |
| Working Capital | 104.49B |
Cash Flow
In the last 12 months, operating cash flow was -48.03 billion and capital expenditures -20.06 billion, giving a free cash flow of -68.09 billion.
| Operating Cash Flow | -48.03B |
| Capital Expenditures | -20.06B |
| Free Cash Flow | -68.09B |
| FCF Per Share | -5,665.15 |
Margins
| Gross Margin | -76.74% |
| Operating Margin | -9,032.13% |
| Pretax Margin | -7,936.63% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -9,881.47% |
Dividends & Yields
Prestige BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -3.87% |
| FCF Yield | -40.01% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Prestige BioPharma has an Altman Z-Score of -0.34. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.34 |
| Piotroski F-Score | n/a |